Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

# Sandoz vs. Amgen A Legal Battle for Patient Access to Biosimilars

In a significant development in the biopharmaceutical sector, Sandoz, a global leader in generic pharmaceuticals and biosimilars, has initiated antitrust litigation against Amgen. This legal action centers around allegations that Amgen has engaged in practices that hinder patient access to etanercept biosimilars in the United States. Etanercept, originally marketed under the brand name Enbrel, is a critical treatment for various autoimmune disea…

Why Sandoz is waging war on Amgen

Sandoz has launched antitrust litigation against Amgen in the United States for blocking competition from cheaper biosimilars, including its Erelzi, which treats a number of disabling inflammatory diseases. Amgen's drug has generated sales of 3.3 billion dollars in the US and can benefit 7.5 million Americans. All the details Swiss generic drug maker Sandoz, a spin-off of Novartis , said it has filed an antitrust lawsuit in the United States aga…

Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit - Pharmaceutical Technology

Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.

Sandoz files antitrust litigation against Amgen regarding entanercept biosimilar

Sandoz is seeking damages in addition to clearing a path for launch.

Sandoz Takes On Amgen: Battle for $3.3B Drug Market Affects 7.5M Patients

Legal challenge seeks to unlock $3.3B biosimilar market, potentially benefiting 7.5M patients. Triple damages sought in landmark antitrust case. Full analysis inside.